- Home
- EIC vs SWKH Comparison
EIC vs SWKH Comparison
Compare EIC & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- SWKH
- Stock Information
- Founded
- EIC N/A
- SWKH 1996
- Country
- EIC United States
- SWKH United States
- Employees
- EIC N/A
- SWKH N/A
- Industry
- EIC Finance/Investors Services
- SWKH Diversified Financial Services
- Sector
- EIC Finance
- SWKH Finance
- Exchange
- EIC Nasdaq
- SWKH Nasdaq
- Market Cap
- EIC 250.6M
- SWKH 210.8M
- IPO Year
- EIC 2019
- SWKH 1999
- Fundamental
- Price
- EIC $16.46
- SWKH $16.60
- Analyst Decision
- EIC
- SWKH
- Analyst Count
- EIC 0
- SWKH 0
- Target Price
- EIC N/A
- SWKH N/A
- AVG Volume (30 Days)
- EIC 116.0K
- SWKH 7.1K
- Earning Date
- EIC 11-14-2023
- SWKH 11-14-2024
- Dividend Yield
- EIC 13.63%
- SWKH N/A
- EPS Growth
- EIC N/A
- SWKH N/A
- EPS
- EIC 0.80
- SWKH 0.94
- Revenue
- EIC N/A
- SWKH $25,767,000.00
- Revenue This Year
- EIC N/A
- SWKH N/A
- Revenue Next Year
- EIC N/A
- SWKH $6.17
- P/E Ratio
- EIC $20.31
- SWKH $17.67
- Revenue Growth
- EIC N/A
- SWKH N/A
- 52 Week Low
- EIC $13.00
- SWKH $15.65
- 52 Week High
- EIC $16.48
- SWKH $18.75
- Technical
- Relative Strength Index (RSI)
- EIC 61.21
- SWKH 52.81
- Support Level
- EIC $15.88
- SWKH $16.40
- Resistance Level
- EIC $16.30
- SWKH $17.25
- Average True Range (ATR)
- EIC 0.25
- SWKH 0.40
- MACD
- EIC 0.06
- SWKH 0.03
- Stochastic Oscillator
- EIC 79.75
- SWKH 68.80
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.